GlassScriptPhysician profile
Muhammad Bhatti
NPI 1427047778
$8,010.97
in general payments reported to CMS, 2019-2025
24 companies · $1,610 in 2025
The $1,610 reported for 2025 was more than what 80% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,520 · 2020: $161 · 2021: $906 · 2022: $1,124 · 2023: $2,257 · 2024: $433 · 2025: $1,610.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,719 · Travel and Lodging: $1,581.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,718.73 |
| Travel and Lodging | $1,581.30 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $3,721.80 | 2019-2025 | Optis, Coroflow, Amplatzer Talisman |
| Medtronic, INC. | $943.67 | 2025 | Symplicity G3 |
| Medtronic Vascular, INC. | $605.69 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $473.86 | 2019-2023 | Seglentis |
| Abiomed | $453.88 | 2019-2025 | Impella |
| Cvrx, INC. | $259.14 | 2021-2022 | |
| Boston Scientific Corporation | $251.56 | 2019-2024 | |
| Merck Sharp & Dohme LLC | $244.77 | 2022-2025 | Verquvo, Capvaxive |
| Biotronik INC. | $138.74 | 2019 | |
| Edwards Lifesciences Corporation | $130.58 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $128.11 | 2022-2025 | Camzyos, Eliquis |
| Lantheus Medical Imaging, INC. | $94.73 | 2019 | |
| Pfizer INC. | $78.34 | 2022-2025 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $77.87 | 2023-2024 | Lifevest |
| Becton, Dickinson and Company | $75.86 | 2025 | Rotarexs 6 F X 135 Cm |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $74.52 | 2023-2025 | Repatha, Repatha |
| Shockwave Medical, INC | $62.40 | 2025 | |
| Sanofi-Aventis U.S. LLC | $56.71 | 2021-2022 | |
| Novartis Pharmaceuticals Corporation | $42.45 | 2020-2023 | |
| Itamar Medical INC | $23.66 | 2025 | Watchpatone |
| Alnylam Pharmaceuticals INC. | $22.71 | 2025 | Amvuttra |
| Lexicon Pharmaceuticals, INC. | $18.38 | 2023 | Inpefa |
| Cardiovascular Systems INC. | $17.08 | 2020 | |
| Astellas Pharma US INC | $14.46 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Muhammad Bhatti listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.